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A Review of Rivaroxaban, an Oral Anticoagulant
Lindsey A. Hallman, fifth-year pharmacy student from Olmsted Falls, Ohio; Chad A. Rounds, fifth-year pharmacy student from Fort Wayne, Ind.;
Rebecca A. Carey, sixth-year pharmacy student from Trenton, Mich.; Nicole R. Hume, sixth-year pharmacy student from London, Ohio;
Ryan W. Naseman, sixth-year pharmacy student from Anna, Ohio; Karen L. Kier, PSPh '82, Ph.D., MSc., RPL
Background

In post-operative patients, limited mobility can lead to increased morbidity and mortality due to venous thromboembolism (VTE), which is a
life-threatening complication consisting of either deep vein thrombosis
(DVT) or pulmonary embolism (PE). Prophylaxis with anticoagulants is
often recommended for this patient group for this reason. 1·3 In general
surgery patients without prophylaxis, DVT incidence is approximately 25
percent. 3 Patients undergoing more mobility-limiting procedures, such as
total hip or knee replacement surgery or hip fracture surgery, DVT rates
are at rates of up to 35-60 percent. With regard to PE, prevalence varies
greatly depending on the site of surgery but overall is an important consideration due to the high potential for patient harm. Without prophylaxis,
general surgery patients have a PE incidence of 1.6 percent, with 0.9
percent fatality. With an increase in procedure complexity, PE incidence
can go as high as 3.6-12.9 percent, such as in hip fracture surgery. 14
The effectiveness of anticoagulation prophylaxis often is weighed
against the safety risks and administration issues of available treatments, and these issues can leave physicians looking for better options.
As addressed in the previous issue of The Pharmacy and Wellness
Review, development of new anticoagulation agents for prophylaxis of
VTE has been underway as drug companies aim to create orally available agents that target the clotting cascade in specific ways to avoid
undesired coagulation while minimizing patient bleeding risk. 5 The goal
of these new therapeutic agents is to ease patient administration and
increase tolerability while being as effective or better than currently
available agents in prevention of VTE. Specific targets for therapy
include Factors Ila and Xa. Select anticoagulants showing promise in
the pipeline include dabigatran, a direct thrombin (Factor Ila) inhibitor,
which was discussed in a previous issue of The Pharmacy and Wellness Review (May 2010), and rivaroxaban, a direct Factor Xa inhibitor.
Dabigatran was recently given approval by the Food and Drug Administration (FDA). Rivaroxaban has been granted approval for use in both
the European Union and Canada since September 2008. 6 Rivaroxaban
was submitted in July 2008 for U.S. FDA approval. It was approved by
the FDA advisory committee but was denied by the FDA with a need for
more information, which the manufacturer, Bayer, is preparing. 3• 5• 6
Rivaroxaban is a competitive, selective and reversible Factor Xa inhibitor. The bioavailability is greater than 80 percent and is not affected
by food, leading to a half-life of approximately nine hours, which may
be prolonged in the elderly. 7 Renal excretion accounts for two-thirds of
elimination, while the rest is eliminated in the feces via P-glycoprotein
and some hepatic metabolism by the CYP450 enzyme system. It is
possible that inhibition of CYP3A4 could cause an increase in plasma
levels. Rivaroxaban has a contraindication in renal failure (CrCI <30 ml/
min) due to lack of evidence. Early dose-finding studies in hip or knee
replacement found rivaroxaban did not have a true dose-response
relationship with regards to efficacy, but bleeding risk did increase
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proportionally with increases in dosage. The optimal dose was found to
be between 5 and 20 mg, and rivaroxaban is available as a 1Omg tablet
in countries where it is approved.
Efficacy
Several trials concluded efficacy exists for regular clinical use of rivaroxaban in patients. The RECORD 1 and 4 trials had a primary efficacy
composite endpoint of any DVT (proximal or distal), confirmed non-fatal
PE, and all cause mortality during treatment. 8•9 The RECORD 4 trial
had 366 patients eligible for the efficacy analysis with symptomatic DVT
during follow-up confirmed by venography or ultra-sound. 9 Using the
composite data, 44.3 percent of patients on enoxaparin 40 mg daily
had some complication included in the composite endpoint. The 10 mg
twice-daily dose of rivaroxaban did considerably better, with only 23.3
percent of patients having a complication (p=0.29). The 5 mg twice-daily
rivaroxaban dose had similar efficacy to enoxaparin, with 40.4 percent
having complications. Major VTE occurred in patients ranging from rates
of 0-6.7 percent with various doses of rivaroxaban versus 4.3 percent
with enoxaparin. All rivaroxaban dose-range groups investigated had
efficacy similar to twice-daily enoxaparin beginning the day after surgery.
Alternatively, RECORD 1 compared 10 mg rivaroxaban to 40 mg enoxaparin in patients receiving VTE prophylaxis after hip arthroplasty and
found rivaroxaban to be more efficacious than enoxaparin. 8 At the end
of the trial, 69 percent of 4,541 patients were included in the superiority
analysis, with venography required for inclusion. The primary composite
endpoint of complications occurred in 1. 1 percent in the rivaroxaban
group and 3.7 percent in the enoxaparin group (p < 0.001 ), with major
VTE occurring in 0.2 percent of the rivaroxaban group contrasted with
2 percent of enoxaparin patients. Major bleeding was observed in 0.3
percent of the rivaroxaban group versus 0.1 percent with enoxaparin.
Another study, RECORD 2, looked at an extended duration of rivaroxaban versus short-term enoxaparin use for prevention of VTE after hip
arthroplasty. 10 This study used a modified intention-to-treat analysis for
the primary efficacy of 864 patients in the rivaroxaban group and 869
patients in the enoxaparin group. The primary endpoint occurred in 2
percent of the rivaroxaban group and 9.3 percent in the enoxaparin
group. The incidence of bleeding was similar in both groups (6.6 percent
for rivaroxaban versus 5.5 percent with enoxaparin). Extended thromboprophylaxis was concluded to be more effective with rivaroxaban than
short-term enoxaparin.
A trial independent of the RECORD series, known as the Einstein Study,
was a randomized, dose-ranging, double-blind, open-labeled study that
compared rivaroxaban to low molecular weight heparin (LMWH) and
vitamin K antagonist (VKA) therapy per hospital protocol until an INR of
2-3 was reached in patients with acute symptomatic DVTs. 11 Of the 543
patients in the study, 449 were eligible to be included in the per-protocol
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analysis. With a primary efficacy composite outcome of symptomatic
recurrent DVT, symptomatic fatal/nonfatal PE and asymptomatic deterioration in negative thrombotic effects, rivaroxaban was found to be more
efficacious than LMWHNKA. The LMWHNKA group had 9 percent of
patients experience the primary efficacy endpoint compared to 5.4-6.6
percent of rivaroxaban patients. With the 5-20 mg rivaroxaban range
deemed to be efficacious, the 20 mg dose was found to be most effective in preventing DVT recurrences.

Safety
The phase II ATLAS trial was a double-blind, open-label, with block
randomization of 1:1 :1 placebo:rivaroxaban (doses 5-20 mg) once
daily:rivaroxaban (2.5-1 Omg) twice daily with at least 225 patients per
tier. 6 The study called for liver function tests to take place once a month
during the study. The safety endpoint consisted of clinically significant bleeding requiring assistance, such as lab tests or surgery. Liver
function tests revealed no significant difference in the rate of alanine
aminotransferase greater than three times the upper limit of normal in
patients given rivaroxaban compared with placebo (3. 7 percent versus
4.5 percent, respectively). Clinically significant bleeding occurred in a
dose-dependent manner compared to placebo. 12
Rivaroxaban was compared to enoxaparin in a randomized, doubleblind/dummy study, active-comparator-controlled, multi-national study in
873 patients undergoing hip replacement surgery that received prophylaxis of VTE between six and eight hours post-operation. 13 The primary
safety outcome was the incidence of major bleeding, which ranged from
O. 7 percent wtth the 10 mg rivaroxaban dose to 5.1 percent with the 40
mg dose. The study determined no significant difference in incidence
of major post-operation bleeding between rivaroxaban and enoxaparin.
A total of 845 patients was used in the safety population data, which
determined a significant dose-response relationship (p=0.0391).13
In RECORD 1 when dosing rivaroxaban, the occurrence of major VTE
decreased while the risk of major bleeding increased compared to
enoxaparin, suggesting the patient's status should be considered when
selecting therapy. 10 A challenge in the approval process for rivaroxaban
is the lack of power for safety outcomes in the studies. Post-marketing
pharmacovigilance should provide more data on the safety of rivaroxaban.

Place In therapy
Based on safety and efficacy data, rivaroxaban has evidence that it
could be an effective treatment in VTE prophylaxis in post-surgical
patients. Further studies, including post-marketing surveillance, could
help to reinforce this evidence. There are no currently published studies
looking into efficacy and safety of rivaroxaban in comparison to warfarin
in VTE. The ROCKET-AF trial looking at rivaroxaban in atrial fibrillation versus warfarin is currently ongoing, and results will help to further
determine rivaroxaban's usefulness long-term. 11

Although rivaroxaban has been shown to be clinically useful in patients,
some concern was raised over the degree of benefit over enoxaparin
in the RECORD trial series results due to inherent trial/design issues.
Specifically, Van Thiel raised awareness in an editorial that enoxaparin
dosing was inconsistent with recommendations in the United States and
that less-than-optimum duration and dosing prevented maximum enoxaparin benefit in comparison to rivaroxaban. 15 Lack of power for differences in major bleeding, as well as some questionable safety evaluations
compared to current recommendations, also weakened the findings of
this extensive study. While these points are justified, the trial program did
demonstrate promising results for rivaroxaban as an atternative agent for
VTE prophylaxis. With varying international standards for prophylaxis and
new CHEST guidelines, which were published after the trials had been
conducted, the issues do not seem to limit rivaroxaban therapy for consideration. Slated to finish in fall 2010, the ROCKET-AF trial will provide
results detailing the clinical comparison of rivaroxaban to warfarin. 11 The
FDA Advisory Panel has requested more data of Bayer, rivaroxaban's
manufacturer, which is not likely to be submitted until late 201 Oor early
2011, meaning FDA approval will be delayed until 2011 at the earliest. 16
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